The roles of tertiary lymphoid structures in chronic diseases.

Nat Rev Nephrol

Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Published: August 2023

AI Article Synopsis

  • Tertiary lymphoid structures (TLSs) are unique, non-capsulated lymphoid tissues that promote immune responses in areas of chronic inflammation, differing from traditional lymph nodes.
  • Research indicates that TLSs exhibit variability in their composition and behavior, leading to conflicting associations with disease outcomes; for example, they can be linked to better outcomes in cancer but worse outcomes in autoimmune diseases and chronic conditions.
  • Understanding the development and function of TLSs at a cellular and molecular level could pave the way for new treatments for chronic diseases like chronic kidney disease.

Article Abstract

Tertiary lymphoid structures (TLSs) are ectopic lymphoid tissues that drive antigen-specific immune responses at sites of chronic inflammation. Unlike secondary lymphoid organs such as lymph nodes, TLSs lack capsules and have their own unique characteristics and functions. The presumed influence of TLSs on the disease course has led to widespread interest in obtaining a better understanding of their biology and function. Studies using single-cell analyses have suggested heterogeneity in TLS composition and phenotype, and consequently, functional correlates with disease progression are sometimes conflicting. The presence of TLSs correlates with a favourable disease course in cancer and infection. Conversely, in autoimmune diseases and chronic age-related inflammatory diseases including chronic kidney disease, the presence of TLSs is associated with a more severe disease course. However, the detailed mechanisms that underlie these clinical associations are not fully understood. To what extent the mechanisms of TLS development and maturation are shared across organs and diseases is also still obscure. Improved understanding of TLS development and function at the cellular and molecular levels may enable the exploitation of these structures to improve therapies for chronic diseases, including chronic kidney disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092939PMC
http://dx.doi.org/10.1038/s41581-023-00706-zDOI Listing

Publication Analysis

Top Keywords

disease course
12
tertiary lymphoid
8
lymphoid structures
8
chronic diseases
8
presence tlss
8
diseases including
8
including chronic
8
chronic kidney
8
kidney disease
8
tls development
8

Similar Publications

Buruli Ulcer Transmission: Environmental Pathways and Implications for Dermatologic Care.

Cutis

December 2024

Michelle R. Anthony is from the University of Arizona College of Medicine, Tucson. Christopher Farkouh is from Rush Medical College, Chicago, Illinois. Parsa Abdi is from Memorial University, St. Johns, Newfoundland, Canada. Dr. Khan is from Kyber Teaching Hospital MTI KTH, Peshawar, Pakistan.

Buruli ulcer (BU) is a necrotizing skin and soft tissue disease caused by Mycobacterium ulcerans that is common in hot and humid climates. Mycobacterium ulcerans is a nontuberculous mycobacterium and ubiquitous acid-fast gram-positive bacillus known to thrive in aquatic environments and water insects. The mode of transmission to humans is poorly understood and varies by geography.

View Article and Find Full Text PDF

Background: Scrub typhus, a disease caused by Orientia tsutsugamushi, triggers systemic vasculitis and is prevalent in Eastern and Southern Asia. This study aimed to uncover the relationship between scrub typhus and autoimmune responses, focusing on antinuclear antibodies (ANAs) and the implications of elevated ANA titers during infection.

Method: Data from a total of 139 patients diagnosed with scrub typhus and 30 healthy controls were retrospectively analyzed through serum samples to assess the levels of ANAs and related autoantibodies.

View Article and Find Full Text PDF

European ILD registry algorithm for self-assessment in interstitial lung diseases (eurILDreg ASA-ILD).

PLoS One

January 2025

European IPF/ILD Registry and Biobank (eurIPFreg/bank, eurILDreg/bank), Giessen, Germany.

Background And Aims: Predicting progression and prognosis in Interstitial Lung Diseases (ILD), especially Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF), remains a challenge. Integrating patient-centered measurements is essential for earlier and safer detection of disease progression. Home monitoring through e-health technologies, such as spirometry and oximetry connected to smartphone applications, holds promise for early detection of ILD progression or acute exacerbations, enabling timely therapeutic interventions.

View Article and Find Full Text PDF

Anaemia and thrombocytopenia are blood-related irregularities linked to an increased likelihood of disease progression, leading to death in people living with human immunodeficiency virus 1 (PLHIV). Severe clinical conditions associated with human immunodeficiency 1 (HIV-1) infection may be related to blood irregularities among PLHIV. The study aimed to examine the factors correlated with blood irregularities among PLHIV receiving antiretroviral treatment in West Papua.

View Article and Find Full Text PDF

Background: While expert optometrists tend to rely on a deep understanding of the disease and intuitive pattern recognition, those with less experience may depend more on extensive data, comparisons, and external guidance. Understanding these variations is important for developing artificial intelligence (AI) systems that can effectively support optometrists with varying degrees of experience and minimize decision inconsistencies.

Objective: The main objective of this study is to identify and analyze the variations in diagnostic decision-making approaches between novice and expert optometrists.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!